Could a hormone Flip-Flop tame tough prostate cancer?
NCT ID NCT05081193
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a two-step treatment in 15 men with metastatic castration-resistant prostate cancer. First, they took high-dose oral testosterone for three 28-day cycles. If the cancer grew, they switched to enzalutamide. The goal was to see if oral testosterone could control the cancer as well as injected testosterone, and whether the sequence might improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
testosterone undecanoate (Jatenzo) and enzalutamide (Xtandi)
What this could lead to
If it works, this could point toward a new treatment sequence that uses high-dose oral testosterone to control prostate cancer before switching to enzalutamide.
What could go wrong
This is a very small, early-phase study (15 men) with no control group. The approach is experimental and may not provide lasting benefit or work for most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21231, United States